Our Mission

Nortis’ vision is no less than to develop the 21st century gold standard for the preclinical testing of drugs and vaccines. We expect our technology will drastically accelerate the discovery and introduction of new therapies and alleviate the use of animals.

About

Nortis is a recognized leader in the emerging field of Organ-on-Chip (OoC) technology. Whilst OoCs are not comprised of electrical circuits, the use of the term “chip” was derived from the silicon-based nature of the platform upon which the technology was conceived. OoCs, also referred to as microphysiological systems (MPS), are revolutionizing the way biomedical science is performed by transcending beyond animal-based research into models that resemble human physiology more accurately.

The introduction of OoC systems demonstrates the next frontier of in vitro biomedical research and drug discovery. Traditional in vitro research is performed on cells or tissue that are removed from their native environments and kept alive in static culture dishes containing growth media. Using OoCs, we are now not only able to engineer tissue from a small population of human cells, but we can also simulate the physiological fluidic flow that the tissue is subject to under normal conditions in vivo through the perfusion of culture media through the engineered microenvironment to which they are introduced.

Nortis’ groundbreaking ParVivo™ System is the worlds first Pre-Seeded Chip platform, where researchers can purchase Chips that have engineered functional living human tissues on them. This “plug-and-play” paradigm removes the need for individual customers to have to engineer tissues themselves, where Chips are produced in-house at Nortis through a highly regulated process that ensures low variability between Chips and the highest quality tissues. We encourage researchers from a multitude of biomedical research areas to get in contact with our team for more information on our Pre-Seeded Chips and how they are suited for your research needs.